Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 355

Results For "SSI"

5626 News Found

Lupin Diagnostics expands footprint in Central India
News | December 22, 2022

Lupin Diagnostics expands footprint in Central India

The expansion in Indore is well-aligned with Lupin Diagnostics’ commitment to improving access to high-quality, reliable, and advanced testing centres and home collection facilities at an affordable price


Lynparza in combination with Abiraterone and Prednisone approved in the EU as treatment for metastatic castration-resistant prostate cancer
Clinical Trials | December 22, 2022

Lynparza in combination with Abiraterone and Prednisone approved in the EU as treatment for metastatic castration-resistant prostate cancer

First PARP inhibitor and new hormonal agent combination approved for these patients in Europe


Supriya Lifescience signs solar agreement with Enrich Energy
Sustainability | December 22, 2022

Supriya Lifescience signs solar agreement with Enrich Energy

The project will generate and supply green energy to fulfill about 50% present consumption of the company


BeatO appoints Dr. Navneet Agrawal as Chief Clinical Officer
People | December 22, 2022

BeatO appoints Dr. Navneet Agrawal as Chief Clinical Officer

He has published more than 100 research papers in several prestigious national and international journals


Indira IVF forays into diagnostic business with ‘Indira Pathlabs’
News | December 21, 2022

Indira IVF forays into diagnostic business with ‘Indira Pathlabs’

Indira IVF integrates diagnostics services with a special focus on women & child care to increase accessibility for patients


Cadila Pharmaceuticals appoints Ashraf Allam as Global COO
People | December 20, 2022

Cadila Pharmaceuticals appoints Ashraf Allam as Global COO

Allam was serving recently as the CEO at Public Investment Fund


Diabetic neuropathic pain field presents significant opportunity for drug developers, says GlobalData
Healthcare | December 20, 2022

Diabetic neuropathic pain field presents significant opportunity for drug developers, says GlobalData

36.4% of patients with diabetic neuropathic pain in 2021 were completely treatment refractory and would benefit from new treatment options.


Ezharima launched in Japan as first dual EZH1 and EZH2 inhibitor therapy for leukemiaLymphoma
News | December 20, 2022

Ezharima launched in Japan as first dual EZH1 and EZH2 inhibitor therapy for leukemiaLymphoma

EZHARMIA is the fifth innovative oncology medicine to be launched in Japan by Daiichi Sankyo in the past three years